Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2336-2345

  Staker, Bart L ^a   Feese, Michael D ^a   Cushman, Mark ^b   Pommier, Yves ^c   Zembower, David ^a   Stewart, Lance ^a   Burgin, Alex B ^a  

^a DeCODE Chemistry & Biostructures   (United States)

^b PURDUE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; ASPARAGINE; CAMPTOTHECIN; DNA TOPOISOMERASE; DOUBLE STRANDED DNA; ED 110; GLUTAMIC ACID; INDENOISOQUINOLINE; INDOLOCARBAZOLE; MJ 238; SA 315F; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; PROTEIN CONFORMATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; BINDING SITES; CAMPTOTHECIN; CARBAZOLES; CRYSTALLOGRAPHY, X-RAY; DNA; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; INDENES; INDOLES; INTERCALATING AGENTS; ISOQUINOLINES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION;

EID: 17144371295     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049146p     Document Type: Article

References (59)

1. Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. On the mechanism of topisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28, 4629-4638.
2. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem 1985, 260, 14873-14878.
3. Champoux, J. J. DNA Topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
4. Stewart, L.; Redinbo, M. R.; Qiu, X.; Hol, W. G. J.; Champoux, J. J. A model for the mechanism of human topoisomerase I. Science 1998, 729, 1534-1541.
5. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692.
6. White, J. H.; Cozzarelli, N. R. A simple topological method for describing stereoisomers of DNA catenanes and knots. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3322-3326.
7. Pourquier, P.; Pilon, A. A.; Kohlhagen, G.; Mazumder, A.; Sharma, A.; et al. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 1997, 272, 26441-26447.
8. Pourquier, P.; Ueng, L. M.; Kohlhagen, G.; Mazumder, A.; Gupta, M.; et al. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 1997, 272, 7792-7796.
9. Lesher, D. T.; Pommier, Y.; Stewart, L.; Redinbo, M. R. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12102-12107.
10. Chrencik, J. E.; Burgin, A. B.; Pommier, Y.; Stewart, L.; Redinbo, M. R. Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. J. Biol. Chem. 2003, 278, 12461-12466.
11. Meng, L.-H.; Liao, Z.-Y.; Pommier, Y. Noncamptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem. 2003, 3, 305-320.
12. Pizzolato, J. F.; Saltz, L. B. The camptothecins. Lancet 2003, 361, 2235-2242.
13. Wall, M. E.; et al. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
14. Bjornsti, M. A.; Benedetti, P.; Viglianti, G. A.; Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 1989, 49, 6318-6323.
15. Pommier, Y.; Kohlhagen, G.; Kohn, K. W.; Leteurtre, F.; Wani, M. C.; et al. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8861-8865.
16. Nitiss, J. L.; Wang, J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7501-7505.
17. Chen, A. Y.; Liu, L. F. DNA topoisomerases: Essential enzymes and lethal targets. Rev. Pharmacol. Toxicol. 1994, 34, 191-218.
18. Horwitz, S. B.; Chang, C. K.; Grollman, A. P. On the mechanism of topisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Mol. Pharmacol. 1971, 7, 632-644.
19. Li, L. H.; Fraser, T. J.; Olin, E. J.; Bhuyan, B. K. Action of camptothecin on mammalian cells in culture. Cancer Res. 1972, 32, 2643-2650.
20. Tanizawa, A.; Kohn, K. W.; Kohlhagen, G.; Leteurtre, F.; Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 1995, 34, 7200-7206.
21. Hsiang, Y. H.; Liu, L. F.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989, 49, 4385-4389.
22. Li, T. K.; Liu, L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 53-77.
23. Sordet, O.; Khan, Q. A.; Kohn, K. W.; Pommier, Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 271-290.
24. Ulukan, H.; Swaan, P. W. Camptothecins: A review of their chemotherapeutic potential. Drugs 2002, 62, 2039-2057.
25. Thompson, J.; Stewart, C. F.; Houghton, P. J. Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta 1998, 1400, 301-319.
26. Rodriguez-Galindo, C.; Radomski, K; Stewart, C. F.; Furman, W.; Santana, V. M.; et al. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol. 2000, 35, 385-402.
27. Mathijssen, R. H.; Loos, W. J.; Verweij, J.; Sparreboom, A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2002, 2, 103-123.
28. Cushman, M.; Cheng, L. Stereoselective oxidation by thionyl chloride leading to the indeno-1,2-c-isoquinoline system. J. Org. Chem. 1978, 43, 3781-3783.
29. Cushman, M.; Jayaraman, M.; Vroman, J. A.; Fukunaga, A. K.; Fox, B. M.; et al. Synthesis of new indeo[1,2-c]isoquinolines: Cytotoxic noncamptothecin topoisomerase I inhibitors. J. Med. Chem. 2000, 43, 3688-3698.
30. Jayaraman, M.; Fox, B. M.; Hollingshead, M.; Kohlhagen, G.; Pommier, Y.; et al. Synthesis of new dihydroindeno[1,2-c]-isoquinoline and indeonisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model. J. Med. Chem. 2002, 45, 242-249.
31. Strumberg, D.; Pommier, Y.; Paull, K.; Jayaraman, M.; Nagafuji, P.; et al. Synthesis of Cytotoxic Indenoisoquinoline topoiomerase I poisons. J. Med. Chem. 1999, 42, 446-457.
32. Kojiri, K.; Kondo, H.; Yoshinari, T.; Arakawa, H.; Nakajima, S.; et al. A new antitumor substance BE-13793C, produced by a streptomycet. Taxonomy, fermentation, isolation, structure determination and biological activity. J. Antibiot. (Tokyo) 1991, 44, 723-728.
33. Staker, B. L.; Hjerrild, K.; Feese, M. D.; Behnke, C. A.; Burgin, A. B., Jr.; et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15387-15392.
34. Fox, B. M.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; et al. Design, synthesis and biological evaluation of cytotoxic 11- alkenylindenoisoquinoline topisomerase I inhibitors and indenoisoquinoline- camptothecin hybrids. J. Med. Chem. 2003, 46, 3275-3282.
35. Fujimori, A.; Harker, W. G.; Kohlhagen, G.; Hoki, Y.; Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995, 55, 1339-1346.
36. Zembower, D. E.; Zhang, H.; Lineswala, J. P.; Kuffel, M. J.; Aytes, S. A.; et al. Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110. Bioorg. Med. Chem. Lett. 1999, 9, 145-150.
37. Andoh, T.; Ishii, K.; Suzuki, Y.; Ikegami, Y.; Kusunoki, Y.; et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5565-5569.
38. Jaxel, C.; Capranico, G.; Kerrigan, D.; Kohn, K. W.; Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991, 266, 20418-20423.
39. Tanizawa, A.; et al. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem 1993, 268, 25463-25468.
40. Antony, S.; Jayaraman, M.; Laco, G.; Kohlhagen, G.; Kohn, K. W.; et al. Differential induction of topoisomerase I-DNA cleaage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: Base sequence analysis and activity against camptothecin-resistant topoisomerase I. Cancer Res. 2003, 63.
41. Nagarajan, N.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; et al. Design, synthesis and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen. J. Med. Chem. 2003, 46, 5712-5724.
42. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 83-106.
43. Bailly, C.; Riou, J. F.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; et al. DNA cleavage by topisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 1997, 36, 3917-3929.
44. Bailly, C. Homocamptothecins: Potent topoisomerase inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol. 2003, 45, 91-108.
45. Chillemi, G.; Fiorani, L.; Benedetti, P.; Desideri, A. Protein concerted motions in the DNA-human topoisomerase complex. Nucleic. Acids Res. 2003, 31, 1525-1535.
46. Bailly, C.; et al. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry 1999, 38, 8605-8611.
47. Urasaki, Y.; Laco, G.; Takebayashi, Y.; Bailly, C.; Kohlhagen, G.; et al. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res. 2001, 61, 504-508.
48. Benedetti, P.; Fiorani, L.; Capuani, L.; Wang, J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 1993, 53, 4343-4348.
49. Chrencik, J. E.; Staker, B. L.; Burgin, A. B., Jr.; Pourquier, P.; Pommier, Y.; et al. Mechanism of Camptothecin Resistance by Human Topoisomerase I Mutations. J. Mol. Biol. 2004.
50. Fertala, J.; Vance, J. R.; Pourquier, P.; Pommier, Y.; Bjornsti, M.-A. Substitutions of Ans-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate. J. Biol. Chem 2000, 275, 15246-15253.
51. Colley, W. C.; van der Merwe, M.; Vance, J. R.; Burgin, A. B., Jr.; Bjornsti, M. A. Substitution of conserved residues within the active site alters the cleavage-religation equilibrium of DNA topoisomerase I. J. Biol. Chem. 2004, 15, 15.
52. Stewart, L.; Ireton, G. C.; Parker, L. H.; Madden, K. R.; Champoux, J. J. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J. Biol. Chem 1996, 271, 7593-7601.
53. Burgin, A. B., Jr.; Huizenga, B. N.; Nash, H. A. A novel suicide substrate for DNA topoisomerases and site-specific recombinases. Nucleic Acids Res. 1995, 23, 2973-2979.
54. Navaza, J. AMORE: An automated package for molecular replacement. Acta Crystallogr. 1994, A50, 157-163.
55. Brünger, A. T.; et al. Crystallography and NMR systems (CNS): A new software system for macromolecular structure determination. Acta Crystallogr. 1998, D54, 905-921.
56. Murshudov, G. N.; Vagin, A. A.; Dodsin, E. J. Refinement of macromolecular structures by maximum likelihood method. Acta Crystallogr. 1997, D53, 240-255.
57. McRee, D. E. XtalView/Xfit - A Versatile Program for Manipulating Atomic Coordinates and Electron Density. J. Struct. Biol. 1999, 125, 156-165.
58. Oldfield, T. X-LIGAND: An application for the automated addition of flexible ligands into electron density. Acta Crystallogr. 2001, D57, 696.
59. Zhang, X. R.; Matthews, B. W. A multi-functional tool for protein structure analysis. J. Appl. Crystallogr. 1995, 28, 624-630.